Device to treat atrial fibrillation superior: study
CHICAGO (Reuters) - Johnson & Johnson's ablation device outperformed drug therapy for the heart rhythm disorder atrial fibrillation in a study that will be used to seek U.S. regulatory approval for the treatment, J&J said on Tuesday.</p><div class="feedflare">
<img src="http://feedproxy.google.com/~f/reuters/healthNews?d=41" border="0"></img> (http://feeds.reuters.com/~f/reuters/healthNews?a=cPe26vOC) <img src="http://feedproxy.google.com/~f/reuters/healthNews?i=NELyUj3d" border="0"></img> (http://feeds.reuters.com/~f/reuters/healthNews?a=NELyUj3d) <img src="http://feedproxy.google.com/~f/reuters/healthNews?i=X5J4ToWU" border="0"></img> (http://feeds.reuters.com/~f/reuters/healthNews?a=X5J4ToWU)
</div><img src="http://feedproxy.google.com/~r/reuters/healthNews/~4/Eg4a4SaVxck" height="1" width="1"/>
http://feeds.reuters.com/~r/reuters/healthNews/~3/Eg4a4SaVxck/idUSTRE4AA55020081111